Related Experiment Video
Updated: Jul 15, 2026
05:31
Transradial Access Chemoembolization for Hepatocellular Carcinoma Patients
Published on: September 20, 2020
Epinephrine-infused CTHA for HCCs.
Osamu Tanaka1, Takuji Yamagami, Takeharu Kato
1Department of Radiology, Graduate School of Medical Science, Kyoto Prefectural University of Medicine, 465 Kajii-cho, Kawaramachi-Hirokoji, Kamigyo-ku, Kyoto, 602-8566, Japan. otanaka@bf7.so-net.ne.jp
Abdominal Imaging
|April 14, 2007
Summary
Hepatic arterial epinephrine infusion improves the visualization of hepatocellular carcinomas by altering arterial blood flow. This technique enhances tumor conspicuity on CT hepatic arteriography (CTHA).
Area of Science:
- Radiology
- Hepatobiliary Imaging
- Interventional Radiology
Background:
- Assessing hepatocellular carcinoma (HCC) requires understanding arterial flow dynamics.
- CT hepatic arteriography (CTHA) is a key imaging modality for liver tumors.
Purpose of the Study:
- To investigate the effect of hepatic arterial epinephrine infusion on relative arterial flow to HCC and adjacent liver tissue.
- To evaluate changes in tumor enhancement and conspicuity using CTHA.
Main Methods:
- Retrospective analysis of 31 pathologically confirmed HCC cases in 16 patients.
- Simultaneous CT during arterial portography (CTAP) and CTHA performed.
- CTHA with and without hepatic arterial epinephrine infusion was compared.
Main Results:
- Visual analysis showed improved HCC enhancement in 83.9% of cases after epinephrine infusion.
- Quantitative analysis revealed a significant increase in HCC CT attenuation (225.8 to 333.9 HU).
- Significant decrease in normal liver parenchyma attenuation (101.1 to 84.6 HU) and increased tumor-to-liver conspicuity (124.6 to 249.2 HU) were observed.
Conclusions:
- Hepatic arterial epinephrine infusion effectively alters relative arterial flow in hepatocellular carcinomas.
- This infusion enhances tumor visualization and conspicuity, improving diagnostic accuracy in CTHA.
Related Concept Videos
01:25Cardiopulmonary Resuscitation IV: Pharmacological Management
Pharmacologic intervention is crucial in treating cardiac arrest patients during ACLS or Advanced Cardiovascular Life Support. The ACLS algorithms guide the administration of specific drugs based on the patient's cardiac arrest rhythm, which includes pulseless ventricular tachycardia (VT), ventricular fibrillation (VF), asystole, and pulseless electrical activity (PEA).EpinephrineIndication: Epinephrine is the first-line drug for all cardiac arrest rhythms.Mechanism of Action: Epinephrine...
01:28Acute Coronary Syndrome IV: Interprofessional Care
IntroductionThe management of Acute Coronary Syndrome (ACS) aims to minimize myocardial damage, preserve myocardial function, and prevent complications.Initial ManagementInpatient management involves continuous cardiac monitoring, preferably in an ICU, focusing on blood pressure, serum sodium, potassium, and creatinine levels, and urine output. Ongoing pharmacologic management is crucial for stabilizing the patient.Supplemental Oxygen: Administer supplemental oxygen if oxygen saturation is...
01:30Adrenergic Agonists: Therapeutic Uses
Adrenergic agonists have diverse therapeutic uses across various medical conditions and emergencies.
Emergency and Intensive Care Unit (ICU) applications: Pressor agents increase blood pressure, heart rate, and contractility in shock and organ failure situations. Dopamine can induce vasodilation and stimulate adrenoceptors. Endogenous catecholamines are effective in treating cardiogenic shock. α2-agonists like clonidine can reverse anesthesia-induced hypertension.
Allergies and anaphylaxis:...
Emergency and Intensive Care Unit (ICU) applications: Pressor agents increase blood pressure, heart rate, and contractility in shock and organ failure situations. Dopamine can induce vasodilation and stimulate adrenoceptors. Endogenous catecholamines are effective in treating cardiogenic shock. α2-agonists like clonidine can reverse anesthesia-induced hypertension.
Allergies and anaphylaxis:...
01:22Heart Failure VI: Adjunct Therapies
Additional therapies for treating patients with heart failure (HF) may include procedural interventions, supplemental oxygen, the management of sleep disorders, and nutritional therapy.Procedural InterventionsImplantable Cardioverter-Defibrillator: For patients at risk of life-threatening arrhythmias due to severe left ventricular dysfunction, an Implantable Cardioverter-Defibrillator (ICD) can detect and terminate these arrhythmias, preventing sudden cardiac death and improving survival rates.
01:26Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers
Receptor tyrosine kinase inhibitors (TKIs) and calcium channel blockers (CCBs) are two critical categories of drugs employed in the treatment of pulmonary artery hypertension (PAH). PAH is a disease that causes high blood pressure in the pulmonary arteries, resulting in chest pain, fatigue, and shortness of breath.
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
01:26Acute Coronary Syndrome V: Nursing Management
Nursing Assessment:Nursing management of acute coronary syndrome (ACS) involves taking the patient's history, focusing on primary complaints such as chest pain, dyspnea, and excessive sweating (diaphoresis), as well as other symptoms like back or jaw pain, nausea, vomiting, palpitations, dizziness, and fatigue. The nurse also reviews the patient's history of cardiac events, risk factors such as hypertension, diabetes, smoking, family history, and current medications.In the objective assessment,...